Hereditary Neuroendocrine Tumor Gene Mutation Panel, NGS
A hereditary neuroendocrine tumor gene mutation panel detects mutations in neuroendocrine tumors (NETs). NETs are rare neoplasms originating from neuroendocrine cells of the endocrine system but also from the gastrointestinal and pulmonary systems. NETs can be sporadic or can arise in patients with hereditary endocrine disorders such as multiple endocrine neoplasia type 1 (MEN-1 syndrome), multiple endocrine neoplasia type 2 syndrome (MEN-2 syndrome), familial paragangliomatosis (FPGLs), neurofibromatosis type 1 (NF1), von Hippel-Lindau disease (VHL), and tuberous sclerosis (TSC). NETs are rare and heterogeneous neoplasms with variable biological behavior. The estimated incidence of NETs is about 1-5 cases/100,000/year. Hereditary NETs generally present at an earlier age, may have multiple tumors localizations or higher secretory activity. NETs usually display slow proliferation but are typically at an advanced stage at presentation. Neuropeptide hypersecretion is a hallmark of these diseases and often results in distinct hormonal syndromes.
MEN-1 Syndrome (MEN-1) is an autosomal dominant disorder characterized by tumors of the parathyroid glands, pituitary, pancreatic islets, and duodenum. Parathyroid tumors causing primary hyperparathyroidism are the most common component of MEN1 and occur in nearly all patients by age 50 years. Hyperparathyroidism is the initial manifestation of the MEN-1 in most patients. Other tumors, including carcinoid tumors, lipomas, and angiofibromas also occur with increased frequency in this disorder. MEN-1 syndrome is a result of mutations of both alleles of the tumor suppressor gene, MEN-1, located on chromosome 11q13. In 70-90% of patients a mutated MEN-1 gene is inherited from an affected parent and the second normal MEN-1allele undergoes somatic mutation resulting in tumorigenesis. Both germline and somatic mutations in MEN-1 are similar and in 80% of cases result in truncation of the protein.
MEN-2 syndrome is an autosomal dominantly inherited tumor syndrome with a prevalence of 1/40,000 individuals. Clinically it can be divided into three types: MEN-2A (55% of all cases), familial medullary thyroid carcinoma (FMTC; 35%– 40%) and MEN-2B (5%–10%). Patients with MEN-2A and MEN-2B have almost a 100% risk of developing medullary thyroid carcinoma (MTC) and about a 50% risk of developing pheochromocytoma. Patients with MEN-2A are also at risk of developing primary hyperparathyroidism, which is not a feature of MEN-2B. MEN-2B is often considered to be a more aggressive form with earlier onset, higher morbidity and mortality. FMTC is a variant of MEN-2A with a strong predilection for MTC but lacks other features of MEN-2A or MEN-2B. Ninety-eight percent of reported MEN-2 families have mutations in the RET gene on chromosome 10 at position q11.21.27.
RET is a proto-oncogene of 21 exons that encodes for a transmembrane receptor tyrosine kinase for members of the glial cell line-derived neurotrophic factor (GDNF) family. Missense mutations resulting in gain-of-function of the RET protein are the cause of the MEN-2 syndrome. The specific mutation in RET predicts the disease aggressiveness and the clinical phenotype in each individual patient. Almost all of the germline point mutations causing MEN-2A, MEN-2B, and FMTC occur in a confined segment either in the extracellular domain of RET, exons 10 and 11, or in the tyrosine kinase domain, exons 13–16.
MEN-4 syndrome is a rare syndrome that is thought to predispose development of parathyroid and pituitary adenomas. The trait is inherited through germline mutations in cell cycle regulator gene CDKN1B. MEN4 is typically inherited in an autosomal dominant fashion and is linked to loss of function mutations in the CDKN1B.
The von Hippel–Lindau syndrome (VHL) has an incidence of ∼1/36 000 individuals and is an inherited in an autosomal dominant fashion. VHL is characterized by increased risk of tumors and cysts: retinal and CNS hemangioblastomas, pheochromocytomas, paragangliomas (PGLs), renal clear cell carcinomas, renal cysts, pancreatic NETs, pancreatic cysts and endolymphatic sac tumors. The syndrome is caused by inactivating mutations in the VHL tumor suppressor gene, located in 3p25 that is involved in the oxygen-sensing pathway through regulation of hypoxia-inducible factors (HIF). Truncation of VHL results in decreased ubiquitination of HIF transcription factors resulting in increased expression of target genes such as VEGFA, etc. VHL is subclassified into type 1 (truncating mutations) and type 2 (missense mutations) diseases that differ in clinical presentation. Subtype 1 presents without pheochromocytoma whereas type 2 typically presents with pheochromocytoma. Subtype 2 may be further subclassified into type 2A which lack renal cell carcinoma or pancreatic cysts and subtype 2B in which they occur.
Familial paraganglioma syndrome is an autosomal dominant disorder characterized by paragangliomas that are typically located in the skull base and neck, but may also arise in the mediastinum, abdomen, pelvis, and urinary bladder. Approximately 5% of skull base and neck paragangliomas and more than 50% of abdominal paragangliomas produce hormones. Most cases of familial paraganglioma are caused by mutation in the succinate dehydrogenase subunit genes (SDHB, SDHC, SDHD, SHDA, and SDHAF2), which encode portions of the mitochondrial complex II. The SDHx genes are believed to function as classical tumor suppressors and tumors generally display loss of heterozygosity (LOH) of the non-mutated allele. Mutations in any of the different SDHx genes, regardless of whether the gene product has catalytic or anchorage function, have been demonstrated to abolish SDHx enzyme activity and lead to an absence of SDH protein expression.
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterized clinically by cutaneous neurofibromas, multiple cafe-au-lait spots, axillary and inguinal freckling, iris hamartomas (Lisch nodules), bony abnormalities, CNS gliomas, pheochromocytomas, and paragangliomas. Approximately 2% of patients with NF1 develop catecholamine-secreting tumors. NF1 is a large gene of 60 exons located on chromosome 17q11.2 that encodes for the protein neurofibromin. The gene product is mainly expressed in the nervous system where it suppresses cell proliferation by promoting the conversion of RAS into the inactive form, thereby inhibiting the oncogenic RAS/RAF/MAP kinase-signaling cascade. Neurofibromin also inhibits the PI3K-AKT mTOR pathway via suppression of RAS. Alterations of the NF1 gene include missense, nonsense, and splice size site mutations, as well as insertions/deletions (indels) and chromosomal rearrangements. Loss of function of the NF1 gene causes mTOR activation and leads to tumor development.
The Tuberosclerosis genes TSC1 (9q34) and TSC2 (16p13.3) are regulated by neurofibromin through mTOR activation thereby linking the three proteins in terms of their potential roles in tumor progression. Disruption of TSC2 in pancreatic beta cells induces beta cell mass expansion in an mTOR-dependent manner.
Panel Components
Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: ATM, ATRX, CDKN1B, DAXX, EPAS1, KTMD2, MAX, MDH2, MEN1, NF1, RET, SDHx, TERT, TMEM127, TP53, TSC1-2, YY1, H-, K- RAS, FH, VHL, SDHA, SDHB, SDHC, SDHD, SDHAF2
- For the diagnosis of MEN-1 syndrome, MEN-2 syndrome, MEN-4 syndrome familial paragangliomatosis (FPGLs), neurofibromatosis type 1 (NF1), von Hippel-Lindau disease (VHL), and tuberous sclerosis (TSC)
- Identifying variants within genes known to be associated with increased risk for hereditary neuroendocrine allowing for predictive testing of at-risk family members
- Therapy selection and disease management
Positive: At least one known pathogenic variant or mutation associated with hereditary neuroendocrine cancer should be detected. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.
Negative for mutation (deletion or duplication) or pathogenic variant in the genes tested
Whole blood (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Frozen: Unacceptable
- Endocr Rev. 2019;40: 506-536. [PMID: 30657883]
- Endocr Relat Cancer. 2018;25: T1-T13. [PMID: 29142004]
- Orphanet J Rare Dis. 2018;13: 205. [PMID: 30428914]
- Cell. 2011;144: 646-74. [PMID: 21376230]
- Oncogene. 1996;12: 481-7. [PMID: 8637703]
- Nat Genet. 1994;6: 70-4. [PMID: 7907913]
- Inherited tumour syndromes. In: Lloyd RV, Osamura RY, Klöppel G, et al.: WHO Classification of Tumors of Endocrine Organs. 4th ed. Lyon, France: International Agency for Research on Cancer, 2017, pp. 262–66.